People with schizophrenia die 15‐20 years prematurely. Understanding mortality risk and
aggravating/attenuating factors is essential to reduce this gap. We conducted a systematic …

Background The Global Burden of Disease Study 2010 (GBD 2010), estimated that a
substantial proportion of the world's disease burden came from mental, neurological and …

Schizophrenia substantially contributes to the burden of mental disorders. Schizophrenia's
burden and epidemiological estimates in some countries have been published, but updated …

Antipsychotics are effective in preventing relapses of schizophrenia, but it is generally
believed that their long‐term use is harmful for patients' physical well‐being. However, there …

People with severe mental illness (SMI)–schizophrenia, bipolar disorder and major
depressive disorder–appear at risk for cardiovascular disease (CVD), but a comprehensive …

Excess mortality in persons with severe mental disorders (SMD) is a major public health
challenge that warrants action. The number and scope of truly tested interventions in this …

Importance It has remained unclear whether there are clinically meaningful differences
between antipsychotic treatments with regard to preventing relapse of schizophrenia, owing …

A meta‐review, or review of systematic reviews, was conducted to explore the risks of all‐
cause and suicide mortality in major mental disorders. A systematic search generated 407 …

Importance Schizophrenia is associated with an increased risk of type 2 diabetes. However,
it is not clear whether schizophrenia confers an inherent risk for glucose dysregulation in the …

The long‐term benefit‐to‐risk ratio of sustained antipsychotic treatment for schizophrenia
has recently been questioned. In this paper, we critically examine the literature on the long …